Publications by authors named "Alison L Allan"

Artemis is a key nuclease involved in the non-homologous end joining repair pathway upon DNA double-stranded breaks and during V(D)J recombination. It participates in various cellular processes and cooperates with various proteins involved in tumorigenesis. Its hereditary mutations lead to several pathological conditions, such as severe combined immunodeficiency with radiation sensitivity.

View Article and Find Full Text PDF
Article Synopsis
  • - The SABR-SYNC trial aims to evaluate the effectiveness of stereotactic ablative radiotherapy (SABR) in patients with oligometastatic cancers that have a synchronous primary tumor, addressing a gap in phase III data currently available.
  • - One hundred and eighty patients will be randomly assigned to receive either standard care treatment or standard care plus SABR, with various dosing and treatment modalities used depending on the physician's clinical judgement.
  • - The trial will focus on overall survival as the main goal, while also examining factors like progression-free survival, quality of life, and potential biomarkers from circulating tumor DNA to improve future treatment decisions.
View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on the critical role of extracellular vesicles (EVs) in tumor development and emphasizes the need for standard protocols in EV research.
  • The researchers isolated EVs from various breast cancer cell lines using ultracentrifugation and size exclusion chromatography, ultimately finding ultracentrifugation to be more effective.
  • They conducted multiple validation tests, identifying differences in EV yields among cell lines and providing technical tips useful for future studies involving EVs in other cell types.
View Article and Find Full Text PDF

Breast cancer is the most prevalent malignancy among women worldwide. Despite significant advances in treatment, it remains one of the leading causes of female mortality. The inability to effectively treat advanced and/or treatment-resistant breast cancer demonstrates the need to develop novel treatment strategies and targeted therapies.

View Article and Find Full Text PDF

Patients with triple-negative breast cancer (TNBC) have an increased propensity to develop lung metastasis. Our previous studies demonstrated that stem-like ALDHCD44 breast cancer cells interact with lung-derived soluble factors, resulting in enhanced migration and lung metastasis particularly in TNBC models. We have also observed that the presence of a primary TNBC tumor can 'prime' the lung microenvironment in preparation for metastasis.

View Article and Find Full Text PDF

Radioresistance is one of the barriers to developing more effective therapies against the most aggressive, triple-negative, breast cancer (TNBC) subtype. In our previous studies, we showed that inhibition of Polo-like Kinase 4 (PLK4) by a novel drug, CFI-400945 significantly enhances the anticancer effects of radiotherapy (RT) compared to single treatment alone. Here we further investigate the role of PLK4 in enhancing radiation effects in TNBC and explore mechanisms of PLK4 inhibition and radiation combinatorial antiproliferative effects.

View Article and Find Full Text PDF

Background: With the shift towards person-centered care (PCC) in oncology, there is a need for parallel evolution of oncology education programs to prepare the next generation of health professionals to deliver effective PCC. These programs should be designed utilizing perspectives from individuals who have lived experience with cancer to ensure that changes to education curricula translate to improved PCC in the clinic.

Objectives: Our goal was to identify existing literature describing such programs as well as identify gaps for further development.

View Article and Find Full Text PDF

For patients with stage I/IIA non-small-cell lung cancer (NSCLC), surgical resection is the standard treatment. However, some of these patients are not candidates for surgery or refuse a surgical option. Definitive stereotactic ablative radiotherapy (SABR) is a standard approach in these patients.

View Article and Find Full Text PDF

Resistance to protein tyrosine kinase inhibitors (TKIs) presents a significant challenge in therapeutic target development for cancers such as triple-negative breast cancer (TNBC), where conventional therapies are ineffective at combatting systemic disease. Due to increased expression, the receptor tyrosine kinases EGFR (epidermal growth factor receptor) and c-Met are potential targets for treatment. However, targeted anti-EGFR and anti-c-Met therapies have faced mixed results in clinical trials due to acquired resistance.

View Article and Find Full Text PDF

Breast cancer is a prominent cause of cancer diagnosis and death in women globally, with over 90% of deaths being attributed to complications that arise from metastasis. One of the common locations for breast cancer metastasis is the lung, which is associated with significant morbidity and mortality. Curative treatments for metastatic breast cancer patients are not available and the molecular mechanisms that underlie lung metastasis are not fully understood.

View Article and Find Full Text PDF

Background: Our aim was to establish if presence of circulating tumor cells (CTCs) predicted worse outcome in patients with non-metastatic esophageal cancer undergoing tri-modality therapy.

Methods: We prospectively collected CTC data from patients with operable non-metastatic esophageal cancer from April 2009 to November 2016 enrolled in our QUINTETT esophageal cancer randomized trial (NCT00907543). Patients were randomized to receive either neoadjuvant cisplatin and 5-fluorouracil (5-FU) plus radiotherapy followed by surgical resection (Neoadjuvant) or adjuvant cisplatin, 5-FU, and epirubicin chemotherapy with concurrent extended volume radiotherapy following surgical resection (Adjuvant).

View Article and Find Full Text PDF
Article Synopsis
  • Advanced or metastatic breast cancer generally has poor survival rates, but local control can be improved through surgical and radiation therapies.
  • A significant challenge in treatment is radioresistance, prompting the need for innovative strategies and approaches that incorporate both radiotherapy and systemic agents for better outcomes.
  • This review explores potential molecular targets and new drugs that could enhance the efficacy of radiation therapy in breast cancer treatment, potentially improving patient outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • * In this study, researchers knocked down the Zeb1 transcription factor in PC-3 prostate cancer cells, which showed a p-EMT phenotype with increased invasion, migration, and changes in cellular markers, demonstrating the significance of p-EMT in aggressive cancer behavior.
  • * Treatment with the de-methylating drug 5-azacytidine reduced the aggressive p-EMT characteristics, and DNA methylation analysis identified 10 potential targets,
View Article and Find Full Text PDF

The lung is one of the deadliest sites of breast cancer metastasis, particularly for triple negative breast cancer (TNBC). We have previously shown that the lung produces several soluble factors that may enhance the metastatic behavior of TNBC, including E-, L-, and P-selectin. In this paper, we hypothesize that lung-derived selectins promote TNBC metastatic behavior and may serve as a potential therapeutic target.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers are developing gene vectors that target cancer cells using tumor-specific promoters, aiming to enhance cancer diagnosis and treatment.
  • The study introduced a novel theranostic system using minicircles, which are compact plasmids designed for efficient delivery of diagnostic and therapeutic functions related to cancer.
  • Their findings showed that these minicircles could effectively detect aggressive prostate tumors through urine tests and selectively kill cancer cells, helping manage tumor growth in high-risk patients.
View Article and Find Full Text PDF

Circulating tumor cells (CTCs) present an opportunity to detect/monitor metastasis throughout disease progression. The CellSearch® is currently the only FDA-approved technology for CTC detection in patients. The main limitation of this system is its reliance on epithelial markers for CTC isolation/enumeration, which reduces its ability to detect more aggressive mesenchymal CTCs that are generated during metastasis via epithelial-to-mesenchymal transition (EMT).

View Article and Find Full Text PDF
Article Synopsis
  • * Identifying BCSCs involves looking for specific cell markers (CD44, CD24) and measuring the activity of the enzyme aldehyde dehydrogenase (ALDH), which helps isolate these cells using techniques like fluorescence-activated cell sorting (FACS).
  • * The text provides a detailed protocol for isolating BCSCs from various sources and outlines various experimental methods (e.g., colony forming assays, mammosphere assays) to study their functions in the lab.
View Article and Find Full Text PDF
Article Synopsis
  • The study explores how triple-negative (TN) breast cancer affects the lung microenvironment, particularly enhancing the extracellular matrix (ECM) and supporting metastasis compared to other breast cancer types.
  • Researchers injected TN and luminal A breast cancer cells into mice, finding that those with TN tumors had increased hematopoietic progenitor cells in bone marrow and higher ECM protein expression in the lungs.
  • Unique proteins linked to metastasis were identified in the lung-conditioned media from TN tumor-bearing mice, suggesting that TN subtype influences premetastatic changes in lung tissues, possibly through extracellular vesicles from tumor cells.
View Article and Find Full Text PDF

The epithelial cells in an adult woman's breast tissue are continuously replaced throughout their reproductive life during pregnancy and estrus cycles. Such extensive epithelial cell turnover is governed by the primitive mammary stem cells (MaSCs) that proliferate and differentiate into bipotential and lineage-restricted progenitors that ultimately generate the mature breast epithelial cells. These cellular processes are orchestrated by tightly-regulated paracrine signals and crosstalk between breast epithelial cells and their tissue microenvironment.

View Article and Find Full Text PDF
Article Synopsis
  • * This study introduces a new microfluidics technique for encapsulating amphiphilic nanomicelles within sodium alginate spheroids, demonstrating improved cytotoxicity against triple-negative breast cancer cells and a sustained drug release.
  • * The research also examined the hydrodynamics of the microchip, focusing on flow rates and dimensionless numbers, confirming the efficient encapsulation of nanomicelles in the alginate shell, which may advance the production of anticancer drug delivery systems.
View Article and Find Full Text PDF

Breast cancer is the most commonly diagnosed cancer in women worldwide, and >90% of breast cancer-related deaths are associated with metastasis. Breast cancer spreads preferentially to the lung, brain, bone and liver; termed organ tropism. Current treatment methods for metastatic breast cancer have been ineffective, compounded by the lack of early prognostic/predictive methods to determine which organs are most susceptible to developing metastases.

View Article and Find Full Text PDF

Background: In PTEN-loss models, the phosphatidylinositol 3-kinase (PI3K)/AKT and androgen receptor signaling pathways cross-regulate by reciprocal feedback whereby inhibition of one activates the other, creating a rationale for co-targeting. We studied the irreversible, pan-isoform inhibitor of Class I PI-3K PX-866 singly (part A) and with abiraterone acetate (AA) in patients on AA with rising prostate-specific antigen (PSA) (part B).

Patients And Methods: The primary endpoint was lack of progression at 12 weeks.

View Article and Find Full Text PDF

Magnetic nanocarriers are useful in targeted cancer therapy. Dasatinib (DAS)-loaded magnetic micelles were prepared for magnetically guided drug delivery. The magnetic nanoplatform is composed of hydrophobic oleic acid-coated magnetite (FeO) core along with DAS encapsulated in amphiphilic zein-lactoferrin self-assembled polymeric micelles.

View Article and Find Full Text PDF

Importance: A blood test to determine whether to treat patients with metastatic castration-resistant prostate cancer (mCRPC) with an androgen receptor signaling (ARS) inhibitor or taxane is an unmet medical need.

Objective: To determine whether a validated assay for the nuclear-localized androgen receptor splice variant 7 (AR-V7) protein in circulating tumor cells can determine differential overall survival among patients with mCRPC treated with taxanes vs ARS inhibitors.

Design, Setting, And Participants: This blinded correlative study conducted from December 31, 2012, to September 1, 2016, included 142 patients with histologically confirmed mCRPC and who were treated at Memorial Sloan Kettering Cancer Center, The Royal Marsden, or the London Health Sciences Centre.

View Article and Find Full Text PDF

The majority of cancer deaths occur because of metastasis since current therapies are largely non-curative in the metastatic setting. The use of in vivo preclinical mouse models for assessing metastasis is, therefore, critical for developing effective new cancer biomarkers and therapies. Although a number of quantitative tools have been previously developed to study in vivo metastasis, the detection and quantification of rare metastatic events has remained challenging.

View Article and Find Full Text PDF